Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Tipo di azione: HORIZON Research and Innovation Actions
- Ente
- Commissione europea
- Territorio
- Unione europea
- Scadenza
- Scadenza · 329 giorni rimasti
Perché questo risultato
- Stato: in programma, scadenza 16/09/2027
